Back to results
US 2016/0251276 A1Published application
Agonist/antagonist compositions and methods of use
OwnerPeter M. Blumberg, Larry V. Pearceinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compositions comprising an agonist and an antagonist, in certain ratios which allow for the onset of agonist action followed quickly by alleviation by antagonist action, and methods of use in personal defense and law enforcement.
Claims37
A composition comprising an effective amount of an agonist and an effective amount of an antagonist,
- wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and
- the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.
A method for incapacitating a subject, comprising:
- (a) providing a non-lethal temporarily incapacitating composition suitable for use in an aerosol or spray application, the incapacitating formulation comprising,
- an effective amount of a TRPV1 agonist, an effective amount of a TRPV1 antagonist, and a solvent system;
- and
- (b) applying the non-lethal temporarily incapacitating formulation to the subject;
- wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.
2 more elements
A method for subduing a subject, comprising:
- (a) providing a non-lethal temporarily incapacitating composition suitable for use in an aerosol or spray application, the incapacitating formulation comprising,
- an effective amount of an opiate agonist, an effective amount of an opiate antagonist, and a solvent system;
- and
- (b) applying the non-lethal temporarily incapacitating formulation to the subject;
- wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.
2 more elements
A pharmaceutical composition in the form of a solid carrier comprising:
- (a) an agonist, (b) an antagonist, (c) an effective solubilizing amount of at least one hydrophiliac surfactant, which is effective to partially or fully solubilize the agonist and antagonist in the solid carrier, and optionally (d) an additive;
- wherein the amount of antagonist does not decrease a maximal response to agonist by more than 20%, compared to agonist alone, at time 0, and the amount of antagonist reduces the response to agonist by at least 80% at 20 minutes.
Dependencies are inferred from the claim text.